| Name | Title | Contact Details |
|---|---|---|
Danny Bell |
Chief Information Officer | Profile |
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
University Hospitals, one of the nation`s leading health care systems, focuses on providing compassionate, quality medical care to patients at convenient locations throughout Northeast Ohio.
Halberd Corporation has acquired exclusive licenses to two issued patents and four provisional patent applications related to the extracorporeal treatment of blood-borne diseases and Cerebrospinal Fluid related diseases, with particular focus on the treatment and rapid detection of Covid-19 and other virus`. The issued patents` extracorporeal technology is applicable to a significant number of the most debilitating and often fatal illnesses affecting mankind: PTSD, CTE (Chronic Traumatic Encephalopathy) and Cancer, among others. We have developed an aggressive timetable to advance the development of these breakthrough technologies through laboratory, hospital, and clinical trials. In addition, we have initiated the development of potential patient trial application lists. Our management team has extensive experience and contacts in the medical/pharmaceutical fields as well as a demonstrated track record of launching new business ventures in a competitive environment.
Founded in 1981, Sunrise Senior Living is credited with establishing the modern era of senior living. Each Sunrise community is dedicated to delivering a personalized approach to senior living where every aspect of the services and environment is built around the specific wants and needs of the individual seniors that call the community home. From purposefully created and thoughtful design, to engaging programming and lifestyle activities and best-in-class quality of care that evolves with the needs of each senior, Sunrise`s industry-leading innovation is built upon its mission to champion quality of life for all seniors. Celebrating 40 years, Sunrise operates more than 240 communities in the United States and Canada serving more than 20,000 residents. With more than 20,000 highly trained team members, Sunrise offers a full range of personalized services, including independent living, assisted living, care for individuals with Alzheimer`s and other forms of dementia, as well as nursing and rehabilitative services.
Northwest Florida Blood Ctr is a Pensacola, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.